Basit öğe kaydını göster

dc.contributor.authorVarol, Mehmet
dc.contributor.authorBenkli, Kadriye
dc.contributor.authorKoparal, Ayse T.
dc.contributor.authorBostancıoğlu, Rakibe B.
dc.date.accessioned2020-11-20T14:41:37Z
dc.date.available2020-11-20T14:41:37Z
dc.date.issued2019
dc.identifier.issn0148-0545
dc.identifier.issn1525-6014
dc.identifier.urihttps://doi.org/10.1080/01480545.2018.1504057
dc.identifier.urihttps://hdl.handle.net/20.500.12809/957
dc.descriptionVAROL, Mehmet/0000-0003-2565-453X; Benkli, Kadriye/0000-0002-9042-8718; Bostancioglu, R. Beklem/0000-0001-6755-6968en_US
dc.descriptionWOS: 000466854400012en_US
dc.descriptionPubMed ID: 30208738en_US
dc.description.abstractDrug design and discovery studies are important because of the prevalence of diseases without available medical cures. New anticancer agents are particularly urgent because of the high mortality rate associated with cancer. A series of mononuclear gold (III) and platinum (II) complexes based on boronated phenylalanine (BPA) were designed and synthesized using 4,4'-dimethyl-2,2'-dipyridyl (L1) or 1,10-phenanthroline-5,6-dion (L2) ligands to obtain promising anticancer drug candidates. Proton nuclear magnetic resonance, infrared, mass spectrometry, and elemental analyses were utilized for chemical characterizations. Cell viability, cancer cell colony formation, endothelial tube formation, and cytoskeleton staining assays were performed using A549 lung adenocarcinoma and human umbilical vein endothelial cells (HUVECs) to investigate preliminary pharmacological activities. L1-based platinum (II) complex (BPA-L1-Pt) was the most promising complex, and has similar activity with the approved chemotherapy drug cis-platinum. Half maximal inhibitory concentration values for BPA-L1-Pt were 9.15 mu M on A549s and 16.61 mu M on HUVECs; the values for cis-platinum were 5.24 mu M on A549s and 23.14 mu M on HUVECs. Consequently, further synthesis studies should be performed to boost the cancer cell selectivity feature of BPA by varying metal and ligand types.en_US
dc.description.sponsorshipAnadolu UniversityAnadolu University [1101S019 - AUBAP]; TUBITAKTurkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [110S077 - SBAG-HD-560]en_US
dc.description.sponsorshipThis study was supported by Anadolu University (Project no: 1101S019 - AUBAP) and TUBITAK (Project no: 110S077 - SBAG-HD-560).en_US
dc.item-language.isoengen_US
dc.publisherTaylor & Francis Ltden_US
dc.item-rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAngiogenesisen_US
dc.subjectDrug Designen_US
dc.subjectCell Survivalen_US
dc.subjectCisplatin (CAS Numberen_US
dc.subject15663-27-1)en_US
dc.subject4-Dihydroxyborylphenylalanine (CAS Numberen_US
dc.subject76410-58-7)en_US
dc.titleDesign and synthesis of novel organometallic complexes using boronated phenylalanine derivatives as potential anticancer agentsen_US
dc.item-typearticleen_US
dc.contributor.departmentMÜ, Fen Fakültesi, Moleküler Biyoloji Ve Genetik Bölümüen_US
dc.contributor.institutionauthorVarol, Mehmet
dc.identifier.doi10.1080/01480545.2018.1504057
dc.identifier.volume42en_US
dc.identifier.issue4en_US
dc.identifier.startpage436en_US
dc.identifier.endpage443en_US
dc.relation.journalDrug and Chemical Toxicologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster